Perspective Therapeutics
Yahoo Finance • last year
Perspective Therapeutics’ VMT-α-NET Protocols Presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium
SEATTLE, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that two upcoming investigator-initiated trials (IIT) were presented at the North American... Full story
Yahoo Finance • last year
Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine
Ten patients received therapy, with an initial response seen in 7 out of 9 evaluable patients to date.Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease. SEA... Full story
Yahoo Finance • last year
Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine
RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will present new clinical and preclinical data for 21... Full story
Yahoo Finance • last year
Perspective Therapeutics’ Cesium-131 Featured at the American Brachytherapy Society’s Annual Conference
RICHLAND, WASHINGTON & CORALVILLE, IOWA, June 27, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and comple... Full story
Yahoo Finance • last year
Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates
VMT-α-NET for neuroendocrine cancers and VMT01 for melanoma are both entering therapeutic trials under IND at leading US institutions. First melanoma patient screened and imaged with [203Pb]VMT01 to determine eligibility for [212Pb]VMT01... Full story
Yahoo Finance • last year
Perspective Therapeutics’ Cesium-131 to be Featured in Presentations at the 2023 American Brachytherapy Society’s Annual Meeting
RICHLAND, Wash & CORALVILLE, IOWA, June 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and... Full story
